Avalyn Pharma Inc. (AVLN)

Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company developing inhaled medicines for rare respiratory diseases, with a focus on pulmonary fibrosis and other interstitial lung diseases. Its approach is to reformulate established oral antifibrotic drugs for inhalation, delivering them directly to the lungs with the aim of improving efficacy and reducing the side effects associated with oral dosing.

The company's pipeline includes AP01, an inhaled form of pirfenidone, and AP02, an inhaled form of nintedanib, both being studied in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. It is also developing AP03, a fixed-dose inhaled combination of the two drugs designed to act through two antifibrotic mechanisms at once.

Avalyn was originally incorporated as Genoa Pharmaceuticals and completed its initial public offering on Nasdaq in 2026.